X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (181) 181
oncology (176) 176
index medicus (148) 148
female (134) 134
male (123) 123
middle aged (120) 120
adult (117) 117
aged (105) 105
sarcoma (93) 93
cancer (84) 84
prognosis (69) 69
treatment outcome (69) 69
chemotherapy (65) 65
tumors (60) 60
imatinib mesylate (56) 56
aged, 80 and over (49) 49
disease-free survival (46) 46
surgery (46) 46
gastrointestinal stromal tumors - drug therapy (44) 44
survival (44) 44
metastasis (43) 43
sarcoma - pathology (43) 43
antineoplastic agents - therapeutic use (42) 42
sarcoma - drug therapy (41) 41
adolescent (37) 37
young adult (37) 37
imatinib (35) 35
retrospective studies (34) 34
benzamides (33) 33
efficacy (33) 33
hematology, oncology and palliative medicine (33) 33
analysis (32) 32
pyrimidines - therapeutic use (32) 32
care and treatment (30) 30
follow-up studies (30) 30
neoplasm staging (30) 30
piperazines - therapeutic use (29) 29
gastrointestinal stromal tumors - pathology (28) 28
gastrointestinal stromal tumors (27) 27
patients (27) 27
clinical trials (26) 26
gist (26) 26
research (25) 25
sarcoma - mortality (25) 25
antineoplastic agents - adverse effects (24) 24
antineoplastic combined chemotherapy protocols - therapeutic use (24) 24
kaplan-meier estimate (24) 24
medicine & public health (24) 24
combined modality therapy (23) 23
disease progression (23) 23
drug therapy (23) 23
soft-tissue sarcoma (23) 23
survival rate (23) 23
antineoplastic agents (22) 22
phase-ii (22) 22
soft tissue neoplasms - pathology (22) 22
therapy (22) 22
trial (22) 22
doxorubicin (21) 21
life sciences (21) 21
mutation (21) 21
soft tissue sarcoma (21) 21
management (20) 20
mesylate (20) 20
soft tissue neoplasms - drug therapy (20) 20
antimitotic agents (19) 19
gastrointestinal neoplasms - drug therapy (19) 19
mutations (19) 19
safety (19) 19
soft-tissue sarcomas (19) 19
survival analysis (19) 19
time factors (19) 19
trabectedin (19) 19
c-kit (18) 18
dose imatinib (18) 18
france (18) 18
antineoplastic agents - administration & dosage (17) 17
cancer therapies (17) 17
prognostic-factors (17) 17
protein kinase inhibitors - therapeutic use (17) 17
sarcoma - therapy (17) 17
solid tumors (17) 17
diagnosis (16) 16
drug administration schedule (16) 16
kit (16) 16
medical research (16) 16
metastases (16) 16
proto-oncogene proteins c-kit - genetics (16) 16
antineoplastic agents, alkylating - therapeutic use (15) 15
gastrointestinal stromal tumors - genetics (15) 15
recurrence (15) 15
risk factors (15) 15
sarcoma - surgery (15) 15
abridged index medicus (14) 14
european organization (14) 14
european-organization (14) 14
ifosfamide (14) 14
liposarcoma (14) 14
phase-ii trial (14) 14
radiotherapy (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Bulletin de l'Academie Nationale de Medecine, ISSN 0001-4079, 04/2012, Volume 196, Issue 4-5, pp. 861 - 884
Journal Article
Revue du Praticien, ISSN 0035-2640, 02/2006, Volume 56, Issue 4, pp. 359 - 367
Journal Article
Oncology (Switzerland), ISSN 0030-2414, 12/2018, Volume 95, Issue 1, pp. 11 - 20
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 03/2004, Volume 91, Issue 3, pp. 263 - 270
Journal Article
Cancer, ISSN 0008-543X, 04/2018, Volume 124, Issue 7, pp. 1449 - 1454
BACKGROUND Tyrosine kinase inhibitors (TKIs) have improved the outcome of patients with gastrointestinal stromal tumors (GISTs), but most patients eventually... 
sunitinib | FDG‐PET | dasatinib | positron emission tomography (PET) | 18F‐fluorodeoxyglucose‐positron emission tomography (FDG‐PET) | imatinib | gastrointestinal stromal tumor (GIST) | tyrosine kinase inhibitor (TKI) | PET | F-fluorodeoxyglucose-positron emission tomography (FDG-PET) | FDG-PET | SRC/ABL KINASE INHIBITOR | DOMAIN | TYROSINE KINASE | F-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) | BMS-354825 | FOLLOW-UP | ABL | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | EARLY PREDICTION | IMATINIB MESYLATE | Prognosis | Follow-Up Studies | Gastrointestinal Neoplasms - drug therapy | Humans | Middle Aged | Dasatinib - therapeutic use | Gastrointestinal Stromal Tumors - diagnostic imaging | Male | Survival Rate | Antineoplastic Agents - therapeutic use | Gastrointestinal Neoplasms - pathology | Gastrointestinal Neoplasms - diagnostic imaging | Gastrointestinal Stromal Tumors - drug therapy | Gastrointestinal Stromal Tumors - pathology | Female | Radiopharmaceuticals | Positron Emission Tomography Computed Tomography - methods | BCR protein | Tyrosine | Imatinib | Toxicity | Emission analysis | Positron emission | Kinases | Patients | Survival | Metabolic response | Confidence intervals | Computed tomography | Surgery | Tomography | Positron emission tomography | Protein-tyrosine kinase | Cancer | Tumors
Journal Article
Future Oncology, ISSN 1479-6694, 05/2018, Volume 14, Issue 10s, pp. 51 - 62
Assessment of health-related quality of life (HRQoL) is essential for holistic care. Greater efforts are required to incorporate HRQoL measures into clinical... 
health-related quality of life | soft tissue sarcoma | patient-centric | shared decision-making | ADJUVANT CHEMOTHERAPY | MULTICENTER | METAANALYSIS | POSTOPERATIVE RADIOTHERAPY | DOXORUBICIN | RANDOMIZED-TRIAL | OPEN-LABEL | CANCER | ONCOLOGY | DOUBLE-BLIND | EUROPEAN-ORGANIZATION
Journal Article
BMC Cancer, ISSN 1471-2407, 11/2014, Volume 14, Issue 1, p. 870
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10028, pp. 1629 - 1637
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1879 - 1886
Journal Article
Journal Article
Annals of Surgery, ISSN 0003-4932, 02/2012, Volume 255, Issue 2, pp. 281 - 286
Journal Article
Future oncology (London, England), 05/2018, Volume 14, Issue 10s, p. 51
Assessment of health-related quality of life (HRQoL) is essential for holistic care. Greater efforts are required to incorporate HRQoL measures into clinical... 
Journal Article
Lancet Oncology, ISSN 1470-2045, 2012, Volume 13, Issue 10, pp. 1045 - 1054
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2009, Volume 27, Issue 1, pp. 31 - 37
Purpose To define the optimal initial management and the best extent of surgery that would optimize margins on primary retroperitoneal sarcomas (RPS). Patients... 
SURVIVAL | OPERATIVE MANAGEMENT | RE-EXCISION | PROGNOSTIC-FACTORS | ONCOLOGY | RESECTION | FOLLOW-UP | CLASSIFICATION | OUTCOMES | SOFT-TISSUE SARCOMA | RADIATION-THERAPY | Multivariate Analysis | Prognosis | Soft Tissue Neoplasms - mortality | Humans | Middle Age